Observational study of COVID-19 prophylactic antibody administration in immunosuppressed patients
- Conditions
- Neoplasms
- Registration Number
- KCT0007617
- Lead Sponsor
- lsan Univeristy Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 100
1) 19 years of age or older
2) Weight 40kg or more
3) If there is no confirmed history of COVID-19 within the last 7 days as of the scheduled administration date of Evusheld
4) Lymphoma (morbidity code: C81, C82, C83, C84, C85, C86), multiple myeloma (C90), acute leukemia (C92, C95) patients who have treated with immunosuppressive agents or chemotherapy within 2 months
5) Patients who have received an allogeneic hematopoietic stem cell transplant within 4 months
6) Patients who have received autologous hematopoietic stem cell transplantation within 2 months
7) Those who voluntarily decided to participate in this study and gave their written consent
1) Contraindications to Evusheld administration
2) denial of consent
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serious adverse reactions
- Secondary Outcome Measures
Name Time Method Antibody detection rate evaluation